- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 209/34 - Oxygen atoms in position 2
Patent holdings for IPC class C07D 209/34
Total number of patents in this class: 543
10-year publication summary
|
38
|
55
|
34
|
30
|
38
|
44
|
20
|
34
|
32
|
14
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Boehringer Ingelheim International GmbH | 4704 |
23 |
| Oncternal Therapeutics, Inc. | 46 |
10 |
| Dana-Farber Cancer Institute, Inc. | 2553 |
9 |
| F. Hoffmann-La Roche AG | 7926 |
8 |
| Ligand Pharmaceuticals Incorporated | 120 |
8 |
| Bayer Cropscience AG | 2062 |
7 |
| Board of Regents, The University of Texas System | 5751 |
6 |
| The Board of Trustees of the University of Illinois | 2683 |
6 |
| ChemoCentryx, Inc. | 389 |
6 |
| Emory University | 1619 |
6 |
| The Salk Institute for Biological Studies | 446 |
6 |
| Regenacy Pharmaceuticals, LLC | 26 |
6 |
| Novartis AG | 10904 |
5 |
| Arcus Biosciences, Inc. | 134 |
5 |
| Celgene Corporation | 1416 |
5 |
| Gilead Sciences, Inc. | 2028 |
5 |
| Honshu Chemical Industry Co., Ltd. | 163 |
5 |
| Musc Foundation for Research Development | 348 |
5 |
| RespiVert Ltd. | 78 |
5 |
| Merck Sharp & Dohme LLC | 3741 |
5 |
| Other owners | 402 |